Loading...
Market
What will be AbbVie's revenue growth rate in Q4 2024?
2
Resolution / Starting Odds
Less than 3% • 25%
3% to 4% • 25%
4% to 5% • 25%
More than 5% • 25%
AbbVie's Q4 2024 financial report
Story
AbbVie Q3 Adjusted EPS $3.00 Beats Estimates; Revenue $14.46B; Skyrizi Sales Up 51%, Raises FY2024 Guidance
Oct 30, 2024, 11:42 AM
AbbVie Inc. reported its third-quarter 2024 financial results, surpassing analysts' expectations. The company's adjusted earnings per share (EPS) increased 1.7% year-over-year to $3.00, exceeding the estimated $2.91, despite an unfavorable impact of $0.04 per share related to acquired in-process research and development (IPR&D) and milestone expenses. On a GAAP basis, diluted EPS was $0.88, a decrease of 12.0%. Revenue rose by 3.8% to $14.46 billion, beating the consensus estimate of $14.28 billion. Strong sales of Skyrizi and Rinvoq offset the decline in Humira revenue. Skyrizi net revenue surged 51% to $3.21 billion, higher than the expected $3.0 billion. Global Humira net revenue declined by 37.2% to $2.22 billion, slightly below the estimated $2.36 billion. AbbVie raised its full-year 2024 adjusted EPS guidance to a range of $10.90 to $10.94, up from the previous range of $10.67 to $10.87, reflecting confidence in its growth prospects. Additionally, the company announced a 5.8% increase in its 2025 dividend.
View original story
Similar markets
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Below 9.5% • 25%
9.5% - 9.6% • 25%
9.7% - 9.8% • 25%
9.9% - 10.0% • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Above 10% • 25%
5% to 10% • 25%
0% to 5% • 25%
Negative growth • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Less than 50% • 25%
50% to 100% • 25%
100% to 150% • 25%
More than 150% • 25%
10-15% • 25%
0-5% • 25%
5-10% • 25%
15% or more • 25%
< 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
> 15% • 25%